While the panel recognized that clinically significant prostate cancer (csPCa) can be MRI-invisible, there was no consensus as to the use of PSMA PET/CT as an adjunct to MRI for patient selection or in follow-up. The gene discussed is FOLH1; the disease is Familial prostate cancer.